Personalis (PSNL) and Moderna (MRNA) announced the companies have signed a new agreement to continue using the Personalis NeXT Platform as part of upcoming clinical studies evaluating mRNA-4157/V940, an investigational personalized cancer vaccine, jointly developed by Moderna and Merck, known as MSD outside of the United States and Canada. The platform, which was also utilized in the vaccine candidate’s Phase 2b clinical study, will be used to sequence genomic information from a patient’s tumor sample to identify the unique genetic mutations that are most likely to generate a tailored antitumor response.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on PSNL:
